Abstracts fi nancial reasons). Biological licenses and tentative approvals were excluded from analysis. Results were obtained using descriptive statistics and chi-squared tests. RESULTS: FDA databases contained a total of 2093 drug product and combination approvals between February 1939 and December 2008. Of those products, 42.3% had generic competition. A total of 595 (28.4%) drug products were discontinued during the study period. Discontinued products included 37.2% of the brand products and 15.6% of the generic products (p 0.001). Safety was the reason for discontinuation for 59 drug products, which represented 2.8% of the approved drugs and accounted for 9.9 % of the product discontinuations. Databases contained 23,931 approvals, including 8,174 NDAs and 15,757 ANDAs. Discontinued applications accounted for 42.3% of all applications, and included 43.9% of the NDAs and 41.8% of the ANDAs approved during the study period. CONCLUSIONS: One-third of the drugs approved by the FDA and more than 40% of the applications were discontinued during the study period. Safety discontinuations constituted a small, but signifi cant, percentage of the discontinuations. Other reasons for discontinuation included product obsolescence and fi nancial reasons. Drug discontinuations pose signifi cant implications for research, product development, and determining societal needs for innovative pharmaceutical products. OBJECTIVES: To assess newspaper coverage of 'off-label drug and medical device use' over the period of 1990 to 2008, explore key themes of discussion, and identify the tone of coverage. METHODS: The ProQuest media database was accessed for news articles published from January 1990 to July 2008 from the top six selling national newspapers. From the initial 1066 articles retrieved, 153 were selected for analysis based on inclusion and exclusion criteria. Main outcome measures were the number of articles published; type of themes covered; headline, content and overall article tone (positive, negative or neutral); specifi c concerns and benefi ts discussed with off-label use; and primary individual interviewed for the article. RESULTS: The articles published on off-label drug use steadily increased over the period of study. The primary themes discussed were concerns over safety and effi cacy (44.4%), benefi ts of off-label prescribing (26.8%), general announcements by the FDA (9.2%), insurance coverage issues (6.5%), and combination of benefi ts and concerns (12.4%). The tone of headlines was mainly neutral (60.1%) although one quarter was negative (25.5%). Within the articles, however, the overall tone was judged more negative for off-label use (39.9% of articles). The majority of articles (58.8%) used clinicians as the primary commenter with other articles using government representatives (11.1%) patients and patient advocates (7.8%), and drug company spokespeople (5.9%) for comments. Inter-coder reliability were in the acceptable ranges, Cohen's kappa (0.7-0.85) and percentage agreement ( 80%). CONCLUSIONS: Off-label drug use has gotten increasing media attention over the years. An understanding of the media coverage enables us to get a better understanding of public perception on this issue. Overall, coverage has been more negative than positive with articles expressing more concerns than benefi ts. Moreover, off-label prescribing is an important and a sensitive issue and hence, media sources should be urged to present this topic with a neutral approach.
PHP18 WASTED MEDICATION: HOW BIG IS THE PROBLEM?
Ryvkin M y , Garavaglia S Medco Health Solutions, Inc., Franklin Lakes, NJ, USA OBJECTIVES: To quantify medication wastage for Lipid Lowering Agents, Antihypertensive Therapy, and Proton Pump Inhibitors. METHODS: This study focused on drug waste for new to therapy patients. The therapy classes under consideration were Lipid Lowering Agents (N 12,978), Antihypertensive Therapy (N 15,975) , and Proton Pump Inhibitors (N 14,365) . The claims came from an aggregate of a segment of Medco Health Solutions clients. We calculated overall percentage of patients that wasted medication as well as percentage of days supply that they wasted. To focus on avoidable waste, we defi ned a wastage event as a switch within therapeutic class. We also stratifi ed the days supply into 3 categories less than or equal to 30 days, between 30 and 90 days, and greater than or equal to 90 days. RESULTS: For Lipid Lowering Therapy: Overall 1.5% of patients had wastage of 0.7% days supplied. Stratifi cation by days: days 30 1.2% of patients and 0.4% of days, 30 days 90 2.4% of patients and 0.9% of days, days 90 2.9% patients and 1.2% of days. For Antihypertensive Therapy: 6.2% patients had wastage of 2% days supplied. Stratifi cation by days: days 30 6.3% of patients and 2.1% of days, 30 days 90 5.1% of patients and 2.1% of days, days 90 5.2% patients and 2% of days. For PPI's: 1.9% patients had wastage of 0.7% days supplied. Stratifi cation by days: days 30 1.9% patients and 0.7% of days, 30 days 90 0.9% of patients and 0.3% of days, days 90 1.8% patients and 0.7% of days. CONCLUSIONS: The drug wastage for the above therapies is very small and so is the difference between the wastage for 30 day supply vs. 90 or greater day supply. Therefore drug wastage should not be a major concern when choosing different plan designs.
PHP19 MEDICATION COSTS AND UTILIZATION IN A HOSPICE CARE
Parekh RH, Kamal KM, Mihalyo M, Runyon A Duquesne University, Pittsburgh, PA, USA OBJECTIVES: To analyze medication costs and utilization in hospice care using PBM claims data from hospices in Ohio. METHODS: A retrospective analysis was conducted using claims from January 1 through December 31 2007 from fi ve hospices in Ohio. The data contains information regarding prescription medication utilization and their costs. Descriptive analyses were conducted to identify ten therapeutic drug classes with the most frequent utilization rates and largest percentage of expenditures. Further, descriptive analyses were conducted to examine the differences in prescription drug count and total cost by therapeutic class and by drug name for each hospice and for all hospices combined. RESULTS: The average number of admissions in each hospice for the calendar year 2007 was 527, 50.6% being male. The drug expenditures for each hospice averaged $498,301 per year. Approximately 1020 different medications under 246 therapeutic classes were found to be utilized in the fi ve hospices. The most frequently utilized therapeutic class of medications, based on prescription medication count included analgesic-narcotics (14.9%) followed by laxatives-cathartics (7.2%), and anti-anxiety drugs (6.7%). Therapeutic classes contributing to the majority of drug expenditures included opioid analgesics (16.5%), SSRIs (4.7%), and antianxiety drugs (4.5%). Medications whose frequency of use contribute to signifi cant expense include morphine sulfate (5.3% -utilization & 4.4% -expenses), and lorazepam (4.4% & 3.1%.). Individual drug products not frequently utilized, although signifi cantly contribute to expenses include fentanyl (3.5%) and low molecular weight heparin products(3.1%). CONCLUSIONS: Although the overall costs for hospice care to Medicare and patients is less as compared to the costs incurred by conventional non-palliative focused care, the cost for medications in a hospice program is significant. Hospices should place emphasis on the utilization of cost effective drugs that can be used among terminally ill patients to provide a high level of quality care with fi scal responsibility.
PHP20 A PROGRAM EVALUATION OF A POLYPHARMACY SUB-POPULATION: MEDICATIONS, EMERGENCY ROOM VISITS, AND HOSPITALIZATIONS
Bresnahan B 1 , Koprowicz K 1 , Roy Choudhury S 2 , Wong E 2 1 University of Washington, Seattle, WA, USA, 2 Premera Blue Cross, Mountlake Terrace, WA, USA OBJECTIVES: We characterized a sub-population of Premera BlueCross members on multiple chronic medications and evaluated an educational, mail-based program designed to address the safety of multiple prescription users. METHODS: Polypharmacy members were selected based on early 2005 chronic prescription claims. Selected members were 19 years of age and were continuously eligible for both prescription and medical benefi ts during the evaluation period (August 2004-January 2007). Pharmacy and medical claims were analyzed to compare monthly medication frequencies and safety-related medical events (emergency room (ER) visits and hospitalizations) between the pre-and post-intervention periods. Generalized linear mixed modeling was used to test for time-period differences in prescriptions. The top ICD-9 codes for ER visits and hospitalizations, as well as the most frequently prescribed medications were reported. Polypharmacy members were grouped into medicationcount categories and prescription and medical event profi les were developed. RESULTS: For the fi nal analysis sample of N 12,962 members (65% female; mean age: 53 years), a comparison of the two periods indicated an increase of approximately 0.5 in mean monthly medication counts during the post-period (6.3 vs. 6.8 prescriptions; p 0.0001). GLMM applied to monthly medications indicated signifi cant differences in the mean number of monthly medications at period start as well as in the slope of monthly medication trends during the periods. ER visits and hospitalizations (safety-related events) were reduced by roughly 1% in the post-period (23% to 22%, 13% to 12%, respectively; both p 0.0001). Reductions in events were observed across medication-count categories. Medications for hypertension, high LDL cholesterol, and diabetes were among the most frequently prescribed in both periods. CONCLUSIONS: This evaluation demonstrates the need for more studies and focus on sub-populations of health challenged members. Well-designed, controlled studies could further test the effects of medical/pharmacist intervention strategies for members taking multiple medications.
PHP21 USING EXPLICIT CRITERIA TO EVALUATE INAPPROPRIATE PRESCRIBING IN ELDERLY OUTPATIENTS: A COHORT STUDY
Abouzaid S 1 , Del Canale S 2 , Maio V 1 1 Thomas Jefferson University, Philadelphia, PA, USA, 2 LHU Parma, Montechiarugolo, Parma, Italy OBJECTIVES: To establish explicit criteria for potentially inappropriate medication prescribing (PIP) for the elderly and assess the prevalence of and factors associated with PIP among elderly residents in the Local Health Unit (LHU) of Parma, Italy according to the developed criteria. METHODS: A nine-member expert panel was convened to develop a list of inappropriate medications refl ecting the Italian prescribing habits. Using the 2002 Beers criteria as a framework, consensus through a two-round Delphi method was reached to classify the identifi ed 23 inappropriate medications into three categories: 17 medications to be always avoided, 3 medications rarely appropriate, and 3 medications with some indications but often misused. A retrospective cohort study using the 2006 Parma LHU automated outpatient prescriptions database was conducted. The cohort comprised 91,741 individuals 65 years
